Objectives: Characterization of the mechanisms driving ceftolozane/tazobactam resistance development in 5 of 47 (10.6%) patients treated for MDR Pseudomonas aeruginosa infections in a Spanish hospital.
Introduction
The increasing prevalence of nosocomial infections caused by MDR or XDR Pseudomonas aeruginosa strains severely compromises the selection of appropriate treatments and is therefore associated with significant morbidity and mortality. [1] [2] [3] This growing threat results from the extraordinary capacity of this pathogen for developing resistance to nearly all available antibiotics by the selection of mutations in chromosomal genes and from the increasing prevalence of transferable resistance determinants, particularly those encoding class B carbapenemases (MBLs) or ESBLs, frequently cotransferred with genes encoding aminoglycoside-modifying enzymes. 4, 5 The emergence of MDR/XDR global clones disseminated in several hospitals worldwide, denominated high-risk clones, adds further concern. 6, 7 The recent introduction of novel b-lactam/b-lactamase inhibitor combinations, namely ceftolozane/tazobactam and ceftazidime/avibactam, which are stable against the chromosomal cephalosporinase AmpC, partially alleviate the urgent clinical need of new agents for combating infections caused by MDR/XDR P. aeruginosa. [8] [9] [10] Thus, the potential emergence of resistance to these antibiotics is of particular concern. Indeed, we reported for the first time some years ago the mechanisms leading to in vitro J Antimicrob Chemother 2018; 73: 658-663 doi:10.1093/jac/dkx424 Advance Access publication 14 November 2017 ceftolozane/tazobactam resistance development 11 and a very few cases of treatment failure due to resistance development have been recently reported. 12 From July 2016 to April 2017, 47 infections caused by MDR/XDR P. aeruginosa were treated with ceftolozane/tazobactam at our hospital. Clinical aspects for this cohort will be presented elsewhere (L. Periañez, X. Mulet, M. L. Martín-Pena, A. Oliver, unpublished data), but this work was aimed at the characterization of the resistance mechanisms driving ceftolozane/resistance development during the treatment of 5 (10.6%) of the patients.
Materials and methods

Clinical strains and susceptibility testing
Five pairs of ceftolozane/tazobactam-susceptible/resistant P. aeruginosa isolates obtained from five patients treated with ceftolozane/tazobactam at Hospital Son Espases (Palma de Mallorca, Spain) between July 2016 and April 2017 were studied. In all cases, the susceptible isolates were obtained before the start of therapy and the resistant isolates during or after completing therapy. MICs of piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, ceftolozane ! 4 mg/L tazobactam, ceftazidime ! 4 mg/L avibactam, imipenem, meropenem, tobramycin, amikacin, ciprofloxacin and colistin were determined by broth microdilution following EUCAST v 7.1 clinical breakpoints and guidelines (http://www.eucast.org/clinical_break points/). STs were documented through MLST using previously described schemes, protocols, available databases and tools (http://pubmlst.org/ paeruginosa).
Characterization of resistance mechanisms
The presence of horizontally acquired b-lactamases was ruled out through previously established phenotypic and molecular (PCR) methods. 13 The expression of the genes encoding the chromosomal b-lactamase AmpC (ampC) and P. aeruginosa efflux pumps, MexAB-OprM (mexB), MexCD-OprJ (mexD), MexEF-OprN (mexF) and MexXY-OprM (mexY), were determined from late-log-phase LB broth cultures at 37 C and 180 rpm by real-time RT-PCR with an Illumina Eco Real-Time PCR System, as previously described. 14 
Resistance genomics
Sequence variation on 146 chromosomal genes related to antimicrobial resistance was evaluated as previously described. 15 Briefly, indexed pairedend libraries were generated from genomic DNA using a commercial library preparation kit (Nextera XT DNA library preparation kit; Illumina) and sequenced on an Illumina MiSeq benchtop sequencer with a MiSeq reagent kit (version 3; Illumina Inc., USA). Obtained paired-ended reads were aligned to P. aeruginosa PAO1 reference genome and sequence variation was further analysed for the 146 chromosomal genes related to antimicrobial resistance. 15 Additionally, the presence of horizontally acquired resistance determinants was further explored using online databases (https:// cge.cbs.dtu.dk//services/ResFinder/).
Characterization of ampC mutants
The documented ampC mutants were cloned in parallel with the WT ampC gene from PAO1 as previously described. 11 Briefly, PCR products obtained with upstream (AmpC-F-EcoRI, 5
0 -TCGAATTCACGACAAAGGACGCCAATCC-3 0 ) and downstream (AmpC-R-HinDIII, TCAAGCTTTCAGCGCTTCAGCGGCACC) primers were digested with EcoRI or HinDIII, ligated to pUCP24, and transformed into Escherichia coli XL1-Blue made competent by CaCl 2 . Transformants were selected in 5 mg/L gentamicin Xgal-IPTG LB agar plates.
The cloned genes obtained from two independent experiments were fully sequenced to ascertain the absence of mutations introduced during PCR amplification. Resulting plasmids were electroporated into an ampC knockout mutant of PAO1 (PADC) and plated in 30 mg/L gentamicin LB agar plates. The obtained transformants were characterized through the determination in triplicate experiments of the MICs for ticarcillin, piperacillin/tazobactam, ceftazidime, cefepime, ceftolozane/tazobactam, ceftazidime/ avibactam, aztreonam, imipenem and meropenem as described above. Representations of the P. aeruginosa PAO1 AmpC b-lactamase structure were performed with the PyMol Molecular Graphic System, v.1.8 (www. pymol.com).
Results and discussion Table 1 shows the antimicrobial susceptibility profiles and main resistance mechanisms documented for the five pairs of ceftolozane/tazobactam-susceptible/resistant P. aeruginosa clinical isolates studied. In all five pairs, the same clone was detected for the susceptible/resistant pairs; the ST175 high-risk clone widespread in Spanish and French hospitals 15, 16 was detected in four of the cases, whereas ST179 was detected in the remaining one.
In the four cases of ST175, the initial isolates were nonsusceptible to ticarcillin, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, ciprofloxacin, tobramycin and amikacin (Table 1) , consistent with the phenotype frequently detected for this high-risk clone. 13, 15 Moreover, genomic analysis revealed the characteristic OprD mutation (Q142X) responsible for carbapenem resistance and the AmpR (G154R) mutation responsible for AmpC overexpression and b-lactam resistance. 13, 15 The four isolates recovered after ceftolozane/ tazobactam treatment had additionally developed ceftolozane/ tazobactam and ceftazidime/avibactam resistance, even if piperacillin/tazobactam and carbapenem MICs were slightly decreased (Table 1) . Remarkably, in addition to the OprD and AmpR mutations, each of the four resistant isolates showed a mutation in AmpC: E247K [GenBank MF481212 (PDC-221)] in one of the isolates, T96I [GenBank MF481213 (PDC-222)] in two and a deletion of 19 amino acids (G229-E247) [GenBank MF481214 (PDC-223)] in the remaining one. In order to demonstrate the effect of these ampC variants, they were cloned in parallel with WT ampC. Comparative MIC data for an ampC-deficient derivative of PAO1 expressing the different AmpC variants are shown in Table 2 . In agreement with the data of the clinical strains, the cloned AmpC variants showed greatly increased ceftolozane/tazobactam and ceftazidime/avibactam MICs compared with WT AmpC. Moreover, MICs of imipenem, cefepime, and particularly piperacillin/tazobactam were lower for the three different AmpC mutants than for the WT. Figure 1 shows P. aeruginosa PAO1 AmpC (PDC-1) structure, highlighting the active site and the mutated residues. E247 is located within the X loop, and the E247K mutation has been previously shown to be selected upon ceftolozane/tazobactam exposure in vitro.
11 Moreover, this mutation has also been documented among highly ceftazidimeresistant clinical strains. 17 Regarding T96, as has been previously demonstrated for Enterobacteriaceae, 18 and as it can be observed for P. aeruginosa in Figure 1 , it directly interacts with E247. Indeed, the T96I substitution has been previously shown to result in an extended-spectrum cephalosporinase (ESAC) phenotype in Enterobacteriaceae. 18 Moreover, even if the specific effect was not
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investigated, the T96I mutation has been recently shown to be selected upon ceftolozane/tazobactam treatment in patients infected by P. aeruginosa. 12 Lastly, the G229-E247 deletion was located within the X loop and obviously included the key residue E247.
On the other hand, the initial ST179 isolate was susceptible to ceftazidime and carbapenems (Table 1) . This patient was initially treated with meropenem (yielding a ceftazidime-susceptible, carbapenem-resistant isolate, not available for further testing) and then with ceftolozane/tazobactam, yielding the final isolate studied. As can be observed in Table 1 , the isolate had acquired carbapenem resistance through the selection of an OprD-inactivating mutation (W417X). Moreover, it had also developed ceftazidime, ceftazidime/avibactam and ceftolozane/tazobactam resistance. Intriguingly, the analysis of ampC sequences failed to yield any mutation. However, the analysis of the horizontally acquired b-lactamases revealed the presence of the classical OXA-10 b-lactamase in the susceptible isolate, but the extended-spectrum OXA-14 enzyme originated by a single N146S mutation 19 in the resistant one. Indeed, extended-spectrum OXAs have already been Resistance to ceftolozane/tazobactam JAC noted to be an infrequent cause of primary ceftolozane resistance. 20, 21 Moreover, we have recently reported the selection of an extended-spectrum OXA-2 derivative (OXA-539) upon ceftazidime treatment, resulting also in ceftolozane/tazobactam and ceftazidime/avibactam resistance. 22 
Conclusions
Ceftolozane/tazobactam has demonstrated higher stability against mutation-driven resistance mechanisms than currently available b-lactams. 8, 11 Moreover, in vitro studies have shown that ceftolozane/tazobactam resistance development requires the accumulation of several mutations, including at least those leading to the overexpression and the structural modification of AmpC. Although ceftolozane/tazobactam has been successfully used for the treatment of MDR/XDR P. aeruginosa infections, a few cases of resistance development have been documented, including our 5 cases (out of 47; 10.6%) and the 3 (14.3%) from Haidar et al. 12 In this sense, it should be noted that the MDR/XDR strains targeted with ceftolozane/tazobactam treatments are typically already resistant to most b-lactams and contain several resistance mechanisms. Such is the case of the widespread high-risk clone ST175, highly disseminated in Spanish and French hospitals, typically showing OprD deficiency and AmpC hyperproduction. Indeed, resistance development in such challenging strains is expected to be more likely than for WT strains, as they already present one of the required mutations (that leading to ampC overexpression) and therefore only one more (leading to AmpC structure modification) mutation is needed. Thus, while infections caused by these MDR/XDR strains might be treatable with ceftolozane/tazobactam, clinical studies evaluating optimal dosing and/or the use of combined therapy are encouraged. In addition to the major role of AmpC mutations, our results are also an alert to the possibility of ceftolozane/tazobactam resistance emergence in strains producing classical horizontally acquired b-lactamases such as OXA-2 or OXA-10, which are frequent in P. aeruginosa. 23 Finally, the fact that development of ceftolozane/tazobactam resistance caused, in all cases, cross-resistance to the novel combination ceftazidime/avibactam adds further concern. Altogether, our findings argue for the need of maintaining an active surveillance of the mechanisms involved in the emergence of resistance to this new valuable antipseudomonal agent.
Funding
